Research released at UN General Assembly week shows tests predicting heart disease and diabetes are among lowest cost solutions for improving Indian health
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Bridging the gap between histopathology and molecular pathology
Subscribe To Our Newsletter & Stay Updated
